Differentiating strong antibiotic producers from weaker ones

When stubborn bugs refuse to make drugs
Biologists at Washington University in St. Louis are using comparative metabologenomics to try to uncover what may be “silencing” Streptomyces and preventing it from producing desirable compounds encoded by its genes. Credit: Blodgett laboratory

An untapped trove of desirable drug-like molecules is hidden in the genomes of Streptomyces bacteria—the same bacteria responsible for the first bacterial antibiotics to treat tuberculosis back in the 1940s.

Isolating them, however, has proved challenging. Now, biologists at Washington University in St. Louis are using comparative metabologenomics to try to uncover what may be "silencing" Streptomyces and preventing it from producing desirable compounds encoded by its genes.

"We examined across the genomes of Streptomyces while at the same time looking at antibiotic outputs," said Joshua Blodgett, assistant professor of biology in Arts & Sciences, the corresponding author of research published in the Proceedings of the National Academy of Sciences (PNAS). "This study highlights comparative metabologenomics as a powerful approach to expose the features that differentiate strong antibiotic producers from weaker ones."

Blodgett's team, including recent Ph.D. graduate Yunci Qi and postdoctoral research associate Keshav Nepal, compared a group of antibiotic-producing of Streptomyces and other nonproducing or poor-producing strains to reveal genomic differences that could affect drug production.

The researchers found a few key differences between the strains. Notably, the good producers of polycyclic tetramate macrolactam (PTM) seemed to benefit from griseorhodin production, which the researchers did not anticipate and originally had tried to eliminate.

But a handful of nucleotides matter, too. Metabologenomics revealed that the presence or absence of two to three nucleotides—essentially letters that make up a genetic message— can tune the switches that drive PTM antibiotic production. This type of fine control previously had been found in certain bacteria that cause disease, but largely had been overlooked in that produce drugs.

"Our work highlights the problem of silent gene clusters and the need to understand them for next-generation drug discovery," Blodgett said. "Comparative metabologenomics is a generally adoptable strategy, and we hope that others might use it to examine their own strains and pathways."


Explore further

New insights into the production of antibiotics by bacteria

More information: Yunci Qi et al, A comparative metabologenomic approach reveals mechanistic insights into Streptomyces antibiotic crypticity, Proceedings of the National Academy of Sciences (2021). DOI: 10.1073/pnas.2103515118
Citation: Differentiating strong antibiotic producers from weaker ones (2021, July 30) retrieved 20 September 2021 from https://phys.org/news/2021-07-differentiating-strong-antibiotic-weaker.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
16 shares

Feedback to editors